Foster Wayne's most recent trade in Atea Pharmaceuticals Inc was a trade of 120,100 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 120,100 | 120,100 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 54,190 | - | - | Common Stock | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 33,333 | 33,333 | - | - | Restricted Stock Units | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 12,062 | 50,128 | - | 3.1 | 36,910 | Common Stock |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,000 | 62,190 | - | - | Common Stock | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 8,000 | 8,000 | - | - | Restricted Stock Units | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 120,100 | 120,100 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 66,666 | - | - | Restricted Stock Units | |
| Atea Pharmaceuticals Inc | Foster Wayne | EVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 33,334 | 33,334 | - | - | Common Stock | |
| Atea Pharmaceuticals Inc | Foster Wayne | EVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 12,477 | 20,857 | - | 3.8 | 47,904 | Common Stock |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 100,000 | 100,000 | - | - | Restricted Stock Units | |
| Atea Pharmaceuticals Inc | Wayne Foster | EVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Wayne Foster | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 71,750 | 71,750 | - | - | Stock Option (Right to Buy) | |
| Atea Pharmaceuticals Inc | Wayne Foster | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) |